

**Amendments To the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-7 (canceled)

8. (currently amended) The compound of Claim 1 ~~23~~ wherein R<sup>2</sup> is selected from:

- (1) -CH<sub>2</sub>-(phenyl),
- (2) -CH<sub>2</sub>-(4-bromophenyl),
- (3) -CH<sub>2</sub>-(3-chlorophenyl),
- (4) -CH<sub>2</sub>-(3,5-difluorophenyl),
- (5) -CH<sub>2</sub>-((2-trifluoromethyl)phenyl),
- (6) -CH<sub>2</sub>-((3-trifluoromethyl)phenyl),
- (7) -CH<sub>2</sub>-((4-trifluoromethyl)phenyl),
- (8) -CH<sub>2</sub>-((3-trifluoromethoxy)phenyl),
- (9) -CH<sub>2</sub>-((3-trifluoromethylthio)phenyl),
- (10) -CH<sub>2</sub>-((3-trifluoromethoxy-5-thiomethyl)phenyl),
- (11) -CH<sub>2</sub>-((3-trifluoromethoxy-5-methoxy)phenyl),
- (12) -CH<sub>2</sub>-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),
- (13) -CH<sub>2</sub>-((3-trifluoromethoxy-5-amino)phenyl),
- (14) -CH<sub>2</sub>-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),
- (15) -CH<sub>2</sub>-((3-trifluoromethoxy-5-sulfonylamino)phenyl),
- (16) -CH<sub>2</sub>-((3,5-bis-trifluoromethyl)phenyl),
- (17) -CH<sub>2</sub>-((3-fluoro-5-trifluoromethyl)phenyl),
- (18) -CH(CH<sub>3</sub>)-((3,5-bis-trifluoromethyl)phenyl), and
- (19) -C(CH<sub>3</sub>)<sub>2</sub>-((3,5-bis-trifluoromethyl)phenyl);
- ~~(20) -CH<sub>2</sub>-(4-(2-trifluoromethyl)pyridyl),~~
- ~~(21) -CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridyl),~~
- ~~(22) -CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridazinyl),~~
- ~~(23) -CH<sub>2</sub>-(4-(2-trifluoromethyl)pyridyl N-oxide), and~~
- ~~(24) -CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridyl N-oxide).~~

9. (currently amended) The compound of Claim 1 ~~23~~ wherein R<sup>3</sup> is heterocycle,

where the heterocycle is selected from: imidazole, pyrimidyl, triazole ~~or~~ and tetrazole, and  
where the heterocycle is unsubstituted or substituted with 1-5 substituents as defined in Claim 23.  
~~where the substituents are independently selected from:~~

- (a) ~~—~~ halo,
- (b) ~~—~~ trifluoromethyl,
- (c) ~~—~~ hydroxy,
- (d) ~~—~~ C<sub>1-3</sub>alkyl,
- (e) ~~—~~ O-C<sub>1-3</sub>alkyl,
- (f) ~~—~~ CO<sub>2</sub>R<sup>9</sup>,
- (g) ~~—~~ CN,
- (h) ~~—~~ NR<sup>9</sup>R<sup>10</sup>, and
- (i) ~~—~~ CONR<sup>9</sup>R<sup>10</sup>.


10. (currently amended) The compound of Claim 23 + wherein R<sup>3</sup> is  
heterocycle,

where the heterocycle is unsubstituted or substituted with 1-3 substituents ~~where the~~  
~~substituents are~~ independently selected from:

- (a) halo,
- (c) hydroxy,
- (d) C<sub>1-3</sub>alkyl,
- (e) -O-C<sub>1-3</sub>alkyl, and
- (f) -CO<sub>2</sub>R<sup>9</sup>.

11. (currently amended) The compound of Claim 23 + wherein R<sup>3</sup> is selected  
from: imidazole, pyrimidyl, triazole ~~or~~ and tetrazole.

12. (currently amended) The compound of Claim 23 + wherein R<sup>3</sup> is selected  
from:



Claims 13-17 (canceled)

18. (currently amended) A pharmaceutical composition which comprises an inert carrier and a the compound of Claim ~~1~~ 23.


19. (withdrawn) A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim ~~1~~ 23.

20. (withdrawn) A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1~~ 23.

21. (withdrawn) A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1~~ 23.

22. (withdrawn) A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1~~ 23.

23. (new) A compound of the formula I:



wherein:

R<sup>1</sup> is selected from the group consisting of:

- (1) -CH<sub>3</sub>,
- (2) -CH<sub>2</sub>CH<sub>3</sub>,
- (3) -CH(CH<sub>3</sub>)<sub>2</sub>,
- (4) -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,
- (5) -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,
- (6) -cyclopropyl,
- (7) -cyclobutyl,
- (8) -cyclopentyl,
- (9) -CH<sub>2</sub>-cyclopropyl,
- (10) -CH<sub>2</sub>-cyclobutyl,
- (11) -CH<sub>2</sub>-cyclopentyl,
- (12) -CH<sub>2</sub>OH,
- (13) -C(CH<sub>3</sub>)<sub>2</sub>(OH),
- (14) -C(CH<sub>2</sub>OH)(CH<sub>3</sub>)<sub>2</sub>,
- (15) -(OH)cyclobutyl,
- (16) -(OH)cyclopentyl,
- (17) -C(CH<sub>3</sub>)<sub>2</sub>(NHCOCH<sub>3</sub>),
- (18) -C(CO<sub>2</sub>H)(CH<sub>3</sub>)<sub>2</sub>,
- (19) -O-CH<sub>3</sub>,
- (20) -O-cyclopentyl,
- (21) -O-CH(CH<sub>3</sub>)<sub>2</sub>,
- (22) -S-CH<sub>3</sub>,
- (23) -S-CF<sub>3</sub>,
- (24) -SO<sub>2</sub>-CH<sub>3</sub>,
- (25) -S-CH(CH<sub>3</sub>)<sub>2</sub>,
- (26) -SO<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>, and

(27)  $\text{-NH-SO}_2\text{-CH}_3$ ;

$\text{R}^2$  is selected from the group consisting of  $\text{-CH}_2\text{-phenyl}$ ,  $\text{-CH(CH}_3\text{)-phenyl}$ , and  $\text{-C(CH}_3\text{)}_2\text{-phenyl}$ , wherein phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

- (a) halo,
- (b) trifluoromethyl,
- (c) trifluoromethoxy,
- (d) hydroxy,
- (e)  $\text{C}_{1-3}$ alkyl,
- (f)  $\text{-O-C}_{1-3}$ alkyl,
- (g)  $\text{-CO}_2\text{-C}_{1-3}$ alkyl,
- (h)  $\text{-CO}_2\text{H}$ ,
- (i)  $\text{-S-C}_{1-3}$ alkyl,
- (j)  $\text{-SO}_2\text{-C}_{1-3}$ alkyl,
- (k)  $\text{-SCF}_3$ ,
- (l)  $\text{-NH}_2$ ,
- (m)  $\text{-NH-SO}_2\text{-C}_{1-3}$ alkyl, and
- (n)  $\text{-SO}_2\text{-NH}_2$ ;

$\text{R}^3$  is a heterocycle, wherein the heterocycle is selected from the group consisting of benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidiny, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof,

wherein the heterocycle is unsubstituted or substituted with 1-5 substituents independently selected from:

- (a) halo,
- (b) trifluoromethyl,
- (c) hydroxy,
- (d) C<sub>1</sub>-3alkyl,
- (e) -O-C<sub>1</sub>-3alkyl,
- (f) -CO<sub>2</sub>R<sup>9</sup>,
- (g) -CN,
- (h) -NR<sup>9</sup>R<sup>10</sup>, and
- (i) -CONR<sup>9</sup>R<sup>10</sup>;

R<sup>4</sup>, R<sup>6</sup>, R<sup>9</sup> and R<sup>10</sup> are H;


R<sup>5</sup> is selected from:


- (a) hydrogen,
- (b) -CH<sub>3</sub>, and
- (c) -O-CH<sub>3</sub>; and

n is the integer 1; or


a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.

24. (new) The compound of Claim 23 which is selected from the group consisting of the compounds below, or a pharmaceutically acceptable salt or individual diastereomer thereof:





Ex. 3



and

Ex. 64